The following is a summary of “Prevalence, risk factors and the impact of tenofovir treatment in SARS-CoV-2 infection and ...

MTX-COVAB is under clinical development by Memo Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

Researchers have shown that people 60 years or older with weakened immunity do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same age group with ...

Regdanvimab is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

INR:2410. west indies women vs australia women's national cricket team Hebo Pharmaceuticals jointly announced the lau ...

INR:9589. live cricket ball by ball Astellas' application for Gilentinib in China to be included in priority review Positive clinical data on IL-6 monoc ...

Discover CDC findings on COVID-19 variants and vaccine protection, revealing key insights into emerging strains and public ...

At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...

Symptoms of respiratory syncytial virus, or RSV, may start off similar to a common cold, with sneezing and a runny nose. But ...